

Eli Lilly and Company Calls Stockholders Meeting

INDIANAPOLIS, April 30, 2014 -- Eli Lilly and Company (NYSE / Euronext Paris / SIX: LLY) today informs its shareholders that it is holding the 2014 Annual General Meeting of stockholders of Lilly on May 5, 2014 at 11:00 a.m. at The Lilly Center Auditorium, Lilly Corporate Center, Indianapolis, Indiana 46285, for the following purposes:

- Election of the five directors listed in the proxy statement to serve three-year terms
- Ratification of Ernst & Young LLP as the principal independent auditors for 2014
- Approval, by non-binding vote, of the compensation paid to the company's named executive officers

We have established the close of business on February 28, 2014 as the record date for determining the registered shareholders entitled to attend, vote or grant proxies to vote at the meeting or any adjournments or postponements of the meeting.

Lilly makes available free of charge on its website, its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, reports filed pursuant to Section 16 of the U.S. Securities Exchange Act of 1934 and amendments to those reports filed with or furnished to the SEC as soon as reasonably practicable after Lilly electronically files these documents with, or furnishes them to, the SEC. These documents are posted on Lilly's website at www.lilly.com — under "Investors."

The SEC maintains a website that contains reports, proxy statements and other information regarding issuers that file electronically with the SEC. These materials may be obtained electronically by accessing the SEC's home page at www.sec.gov.

To obtain copies of Lilly's definitive proxy statement for its 2014 Annual General Meeting, and the necessary documents to vote your shares, please consult Lilly's website at www.lilly.com — under "Investors" or call +317-433-5112.

Eli Lilly and Company
Investor Relations
Lilly Corporate Center
Indianapolis, Indiana 46285, U.S.A.

Contact:
(317) 276-5795 – Mark E. Taylor (Media)
(317) 655-6874 – Philip Johnson (Investors)

SOURCE Eli Lilly and Company